← 返回

多维组学框架鉴定 GPR35 为结直肠癌 M2 巨噬细胞活化驱动因素及不良预后标志

英文原题:A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer.

查看英文原题

A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer.

PubMed 2026/02/18(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的研究结果确定了 GPR35 是一种新的癌细胞内在的免疫逃逸和免疫治疗耐药驱动因子,将其定位为一个有前景的治疗靶点,可使“冷”CRC 肿瘤对免疫检查点阻断敏感。

研究思路结论见上方概要

结直肠癌(CRC)仍然是全球癌症死亡的主要原因,其治疗结果在很大程度上依赖于肿瘤微环境(TME)。尽管免疫疗法已经彻底改变了特定亚群患者的治疗,但大多数患者中驱动免疫逃逸的机制仍不清楚。

在本研究中,我们通过整合多队列scRNA-seq数据,构建了CRC TME的全面单细胞图谱。

通过非负矩阵分解(NMF),我们识别出九个肿瘤内异质性元程序(MPs),其中MP8与M2巨噬细胞活化稳健相关。高维WGCNA进一步确定GPR35为MP8相关基因网络中的主调控因子。跨四个独立队列的临床分析验证了GPR35是预后不良的显著预测因子。在功能上,体外敲低GPR35显著损害了CRC细胞的增殖、迁移和侵袭。在机制上,GPR35高表达 orchestrated 一个免疫排斥微环境,其特征为细胞毒性T细胞和NK细胞募集减少,但矛盾的是免疫检查点表达升高。此外,GPR35表达与八个已确立的免疫治疗应答特征负相关,并与侵袭性突变景观相关。

展开英文摘要原文

In this study, we constructed a comprehensive single-cell atlas of the CRC TME by integrating multi-cohort scRNA-seq data.

Through non-negative matrix factorization (NMF), we identified nine intratumoral heterogeneity meta-programs (MPs), among which MP8 was robustly linked to M2 macrophage activation. High-dimensional WGCNA further pinpointed GPR35 as a master regulator within the MP8-associated gene network. Clinical analysis across four independent cohorts validated GPR35 as a significant predictor of poor prognosis. Functionally, GPR35 knockdown in vitro markedly impaired CRC cell proliferation, migration, and invasion. Mechanistically, high GPR35 expression orchestrated an immune-excluded microenvironment characterized by diminished cytotoxic T cell and NK cell recruitment, yet paradoxically elevated immune checkpoint expression. Furthermore, GPR35 expression was negatively correlated with eight established immunotherapy response signatures and associated with aggressive mutational landscapes. DISCUSSION: Collectively, our findings identify GPR35 as a novel cancer cell-intrinsic driver of immune evasion and immunotherapy resistance, positioning it as a promising therapeutic target to sensitize "cold" CRC tumors to immune checkpoint blockade.

论文信息

作者
Guan S、Zhu L、Tian Y、Chen H、Jiang Y、Huang C、Shi Y、Lin D
第一作者单位
Department of Colorectal Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.China
通讯作者单位
Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.China
期刊
Frontiers in immunology2026
原文标识
PubMed 41789103 · DOI 10.3389/fimmu.2026.1783260